Nitric oxide modulation of the Basal Ganglia circuitry: Therapeutic implication for Parkinson's disease and other motor disorders

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 7, 2011, Pages 777-791

  Pierucci, Massimo ^a,b   Galati, Salvatore ^c   Valentino, Mario ^a   Di Matteo, Vincenzo ^d   Benigno, Arcangelo ^e   Pitruzzella, Alessandro ^b,e   Muscat, Richard ^a   Di Giovanni, Giuseppe ^a,b,e,f  

^a UNIVERSITY OF MALTA   (Malta)

^b Istituto EuroMediterraneo di Scienza e Tecnologia   (Italy)

^c Ospedale Civico Lugano   (Switzerland)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche   (Italy)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Basal ganglia; Dyskinesia; Motor disorders; Nitric oxide; Parkinson's disease; Selective nitrergic drugs

Indexed keywords

ANTIPARKINSON AGENT; ARGININE; GUANOSINE PHOSPHATE; LEVODOPA; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE; PLACEBO;

BASAL GANGLION; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DYSKINESIA; GLOBUS PALLIDUS; HUMAN; LEVODOPA INDUCED DYSKINESIA; MOTOR CONTROL; MOTOR DYSFUNCTION; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMUS;

EID: 81155131951     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711798072329     Document Type: Review

References (196)

1. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-376.
2. Bian, K.; Murad, F. Nitric oxide (NO)-biogeneration, regulation, and relevance to human diseases. Front. Biosci., 2003, 8, d264-278.
3. Dawson, V.L.; Dawson, T.M. Nitric oxide in neurodegeneration. Prog. Brain Res., 1998, 118, 215-229.
4. Arnold, W.P.; Mittal, C.K.; Katsuki, S.; Murad, F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. USA, 1977, 74, 3203-3207.
5. Bredt, D.S.; Hwang, P.M.; Snyder, S.H. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature, 1990, 347, 768-770.
6. Choi, Y.B.; Lipton, S.A. Redox modulation of the NMDA receptor. Cell. Mol. Life Sci., 2000, 57, 1535-1541.
7. Graybiel, A.M.; Canales, J.J. The neurobiology of repetitive behaviors: clues to the neurobiology of Tourette syndrome. Adv. Neurol., 2001, 85, 123-131.
8. Mink, J.W.; Thach, W.T. Basal ganglia intrinsic circuits and their role in behavior. Curr. Opin. Neurobiol., 1993, 3, 950-957
9. Wichmann, T.; Delong, M.R. Anatomy and physiology of the basal ganglia: relevance to Parkinson's disease and related disorders. Handb. Clin. Neurol., 2007, 83, 1-18.
10. Mena-Segovia, J.; Bolam, J.P.; Magill, P.J. Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? Trends Neurosci., 2004, 27, 585-588.
11. DeLong, M.R.; Wichmann, T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol., 2007, 64, 20-24.
12. Flaherty, A.W.; Graybiel, A.M. Corticostriatal transformations in the primate somatosensory system. Projections from physiologically mapped body-part representations. J. Neurophysiol., 1991, 66, 1249-1263.
13. DeLong, M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci., 1990, 13, 281-285.
14. Alexander, G.E.; Crutcher, M.D.; DeLong, M.R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, prefrontal and limbic functions. Prog. Brain Res., 1990, 85, 119-146.
15. Parent, A.; Carpenter, M.B. Carpenter's Human Neuroanatomy; 9th ed.; Williams & Wilkins; Baltimore, 1996.
16. Joel, D.; Weiner, I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience, 2000, 96, 451-474.
17. Kropotov, J.D.; Etlinger, S.C. Selection of actions in the basal ganglia-thalamocortical circuits: review and model. Int. J. Psychophysiol., 1999, 31, 197-217.
18. Grillner, S.; Hellgren, J.; Menard, A.; Saitoh, K.; Wikstrom, M.A. Mechanisms for selection of basic motor programs: roles for the striatum and pallidum. Trends Neurosci., 2005, 28, 364-370.
19. Blair, R.J. Facial expressions, their communicatory functions and neuro-cognitive substrates. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2003, 358, 561-572.
20. Reynolds, J.N.; Hyland, B.I.; Wickens, J.R. A cellular mechanism of reward-related learning. Nature, 2001, 413, 67-70.
21. Pisani, A.; Centonze, D.; Bernardi, G.; Calabresi, P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov. Disord., 2005, 20, 395-402.
22. Del-Bel, E.A.; Bermúdez-Echeverry, M.; Salum, C.; Raisman-Vozari, R. In: The Basal Ganglia Pathophysiology: Recent Advances. Di Giovanni, G., Ed.; Transworld Research Network: Kerala, 2007, pp. 129-158.
23. Egberongbe, Y.I.; Gentleman, S.M.; Falkai, P.; Bogerts, B.; Polak, J.M.; Roberts, G.W. The distribution of nitric oxide synthase immunoreactivity in the human brain. Neuroscience, 1994, 59, 561-578.
24. Eve, D.J.; Nisbet, A.P.; Kingsbury, A.E.; Hewson, E.L.; Daniel, S.E.; Lees, A.J.; Marsden, C.D.; Foster, O.J. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res. Mol. Brain Res., 1998, 63, 62-71.
25. Garthwaite, J.; Boulton, C.L. Nitric oxide signaling in the central nervous system. Annu. Rev. Physiol., 1995, 57, 683-706.
26. Leontovich, T.A.; Mukhina, Y.K.; Fedorov, A.A. Neurons of the basal ganglia of the human brain (striatum and basolateral amygdala) expressing the enzyme NADPH-d. Neurosci. Behav. Physiol., 2004, 34, 277-286.
27. Nisbet, A.P.; Foster, O.J.; Kingsbury, A.; Lees, A.J.; Marsden, C.D. Nitric oxide synthase mRNA expression in human subthalamic nucleus, striatum and globus pallidus: implications for basal ganglia function. Brain Res. Mol. Brain Res., 1994, 22, 329-332.
28. Vincent, S.R.; Kimura, H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience, 1992, 46, 755-784.
29. Johnson, M.D.; Ma, P.M. Localization of NADPH diaphorase activity in monoaminergic neurons of the rat brain. J. Comp. Neurol., 1993, 332, 391-406.
30. Gonzalez-Hernandez, T,Rodriguez M.Compartmental organization and chemical profile of dopaminergic and GABAergic neurons in the substantia nigra of the rat. J. Comp. Neurol., 2000, 421, 107-135.
31. Govsa, F.; Kayalioglu, G. Relationship between nicotinamide adenine dinucleotide phosphate-diaphorase-reactive neurons and blood vessels in basal ganglia. Neuroscience, 1999, 93, 1335-1337.
32. Niijima, K.; Yoshida, M. Activation of mesencephalic dopamine neurons by chemical stimulation of the nucleus tegmenti pedunculopontinus pars compacta. Brain Res., 1988, 451, 163-171.
33. Vincent, S.R.; Satoh, K.; Armstrong, D.M.; Panula, P.; Vale, W.; Fibiger, H.C. Neuropeptides and NADPH-diaphorase activity in the ascending cholinergic reticular system of the rat. Neuroscience, 1986, 17, 167-182.
34. Klejbor, I.; Domaradzka-Pytel, B.; Ludkiewicz, B.; WÃ jcik, S.; MoryÅ, J. The relationships between neurons containing dopamine and nitric oxide synthase in the ventral tegmental area. Folia Histochem. Cytobiol., 2004, 42, 83-87.
35. Gonzalez-Hernandez, T.; Afonso-Oramas, D.; Cruz-Muros, I. Phenotype, compartmental organization and differential vulnerability of nigral dopaminergic neurons. J. Neural Transm. Suppl, 2009, 21-37.
36. Del Bel, E.A.; Guimaraes, F.S. Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice. Psychopharmacology, 2000, 147, 356-361.
37. Gomes, M.Z.; Del Bel, E.A. Effects of electrolytic and 6-hydroxydopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase. Brain Res. Bull., 2003, 62, 107-115.
38. Chalimoniuk, M.; Lukacova, N.; Marsala, J.; Langfort, J. Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuroscience, 2006, 141, 1033-1046.
39. He, Y.; Imam, S.Z.; Dong, Z.; Jankovic, J.; Ali, S.F.; Appel, S.H.; Le, W. Role of nitric oxide in rotenone-induced nigro-striatal injury. J. Neurochem., 2003, 86, 1338-1345.
40. Barthwal, M.K.; Srivastava, N.; Dikshit, M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep., 2001, 6, 297-302.
41. Bernacer, J.Prensa L,Gimenez-Amaya J.M.Morphological features, distribution and compartmental organization of the nicotinamide adenine dinucleotide phosphate reduced-diaphorase interneurons in the human striatum.J. Comp. Neurol. 2005, 489, 311-327.
42. Johannes, S.; Reif, A.; Senitz, D.; Riederer, P.; Lauer, M. NADPH-diaphorase staining reveals new types of interneurons in human putamen. Brain Res., 2003, 980, 92-99.
43. West, A.R.; Galloway, M.P.; Grace, A.A. Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse, 2002, 44, 227-245.
44. Di Matteo, V.; Pierucci, M.; Benigno, A.; Esposito, E.; Crescimanno, G.; Di Giovanni, G. Critical role of nitric oxide on nicotine-induced hyperactivation of dopaminergic nigrostriatal system: electrophysiological and neurochemical evidence in rats. CNS Neurosci. Ther., 2010, 16, 127-136.
45. Di Matteo, V.; Benigno, A.; Pierucci, M.; Giuliano, D.A.; Crescimanno, G.; Esposito, E.; Di Giovanni, G. 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. Ann. NY Acad. Sci., 2006, 1089, 462-471.
46. Di Matteo, V.; Pierucci, M.; Benigno, A.; Crescimanno, G.; Esposito, E.; Di Giovanni, G. Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study. Ann. NY Acad. Sci., 2009, 1155, 309-315.
47. Di Matteo, V.; Pierucci, M.; Benigno, A.; Orban, G.; Crescimanno, G.; Esposito, E.; Di Giovanni, G. Electrophysiological and neurochemical characterization of 7-nitroindazole and molsidomine acute and sub-chronic administration effects in the dopaminergic nigrostrial system in rats. J. Neural Transm. Suppl., 2009, 173-182.
48. West, A.R.; Grace, A.A. Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J. Neurophysiol., 2000, 83, 1796-1808.
49. Trabace, L.; Kendrick, K.M. Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J. Neurochem., 2000, 75, 1664-1674.
50. Buyukuysal, R.L. Effect of nitric oxide donors on endogenous dopamine release from rat striatal slices. I: Requirement to antioxidants in the medium. Fundam. Clin. Pharmacol., 1997, 11, 519-527.
51. Cox, B.A.; Johnson, S.W. Nitric oxide facilitates N-methyl-D-aspartate-induced burst firing in dopamine neurons from rat midbrain slices. Neurosci. Lett., 1998, 255, 131-134.
52. Schilstrom, B.; Mameli-Engvall, M.; Rawal, N.; Grillner, P.; Jardemark, K.; Svensson, T.H. Nitric oxide is involved in nicotine- induced burst firing of rat ventral tegmental area dopamine neurons. Neuroscience, 2004, 125, 957-964.
53. Di Matteo, V.; Pierucci, M.; Di Giovanni, G.; Benigno, A.; Esposito, E. The neurobiological bases for the pharmacotherapy of nicotine addiction. Curr. Pharm. Des., 2007, 13, 1269-1284.
54. Southan, G.J.; Szabo, C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol., 1996, 51, 383-394.
55. Meyer, R.C.; Spangler, E.L.; Patel, N.; London, E.D.; Ingram, D.K. Impaired learning in rats in a 14-unit T-maze by 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, is attenuated by the nitric oxide donor, molsidomine. Eur. J. Pharmacol., 1998, 341, 17-22.
56. Castagnoli, K.; Palmer, S.; Anderson, A.; Bueters, T.; Castagnoli Jr, N. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1 - methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol., 1997, 10, 364-368.
57. Boireau, A.; Dubedat, P.; Bordier, F.; Imperato, A.; Moussaoui, S. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation. Neuropharmacology, 2000, 39, 1016-1020.
58. Thomas, B.; Saravanan, K.S.; Mohanakumar, K.P. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem. Int., 2008, 52, 990-1001.
59. Desvignes, C.; Bert, L.; Vinet, L.; Denoroy, L.; Renaud, B.; Lambas-Senas, L. Evidence that the neuronal nitric oxide synthase inhibitor 7-nitroindazole inhibits monoamine oxidase in the rat: in vivo effects on extracellular striatal dopamine and 3,4- dihydroxyphenylacetic acid. Neurosci. Lett., 1999, 261, 175-178.
60. Mercuri, N.B.; Bonci, A.; Siniscalchi, A.; Stefani, A.; Calabresi, P.; Bernardi, G. Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study. Br. J. Pharmacol., 1996, 117, 528-532.
61. Simola, N.; Morelli, M.; Carta, A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res., 2007, 11, 151-167.
62. Del Bel, E.A.; da Silva, C.A.; Guimaraes, F.S. Catalepsy induced by nitric oxide synthase inhibitors. Gen. Pharmacol., 1998, 30, 245-248.
63. Del Bel, E.A.; da Silva, C.A.; Guimaraes, F.S.; Bermudez-Echeverry, M. Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur. J. Pharmacol., 2004, 485, 175-181.
64. Del Bel, E.A.; Souza, A.S.; Guimaraes, F.S.; da-Silva, C.A.; Nuccida-Silva, L.P. Motor effects of acute and chronic inhibition of nitric oxide synthesis in mice. Psychopharmacology, 2002, 161, 32-37.
65. Marras, R.A.; Martins, A.P.; Del Bel, E.A.; Guimaraes, F.S. L-NOARG, an inhibitor of nitric oxide synthase, induces catalepsy in mice. Neuroreport, 1995, 7, 158-160.
66. Del Bel, E.A.; Guimaraes, F.S.; Bermudez-Echeverry, M.; Gomes, M.Z.; Schiaveto-de-souza, A.; Padovan-Neto, F.E.; Tumas, V.; Barion-Cavalcanti, A.P.; Lazzarini, M.; Nucci-da-Silva, L.P.; de Paula-Souza, D. Role of nitric oxide on motor behavior. Cell. Mol. Neurobiol., 2005, 25, 371-392.
67. Del-Bel, E.A.; Guimaraes, F.S.; Joca, S.R.; Echeverry, M.B.; Ferreira, F.R. Tolerance to the cataleptic effect that follows repeated nitric oxide synthase inhibition may be related to functional enzymatic recovery. J. Psychopharmacol. (Oxford, England), 2010, 24, 397-405.
68. Sugaya, K.; McKinney, M. Nitric oxide synthase gene expression in cholinergic neurons in the rat brain examined by combined immunocytochemistry and in situ hybridization histochemistry. Brain Res. Mol. Brain Res., 1994, 23, 111-125.
69. West, A.R.; Grace, A.A. Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J. Neurophysiol., 2000, 83, 1796-1808.
70. Sammut, S.; Bray, K.E.; West, A.R. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity. Psychopharmacology, 2007, 191, 793-803.
71. Sammut, S.; Dec, A.; Mitchell, D.; Linardakis, J.; Ortiguela, M.; West, A.R. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neuropsychopharmacology, 2006, 31, 493-505.
72. Sammut, S.; Park, D.J.; West, A.R. Frontal cortical afferents facilitate striatal nitric oxide transmission in vivo via a NMDA receptor and neuronal NOS-dependent mechanism. J. Neurochem., 2007, 103, 1145-1156.
73. Galati, S.; D'Angelo, V.; Scarnati, E.; Stanzione, P.; Martorana, A.; Procopio, T.; Sancesario, G.; Stefani, A. In vivo electrophysiology of dopamine-denervated striatum: focus on the nitric oxide/cGMP signaling pathway. Synapse, 2008, 62, 409-420.
74. Di Giovanni, G.; Ferraro, G.; Sardo, P.; Galati, S.; Esposito, E.; La Grutta, V. Nitric oxide modulates striatal neuronal activity via soluble guanylyl cyclase: an in vivo microiontophoretic study in rats. Synapse, 2003, 48, 100-107.
75. Microiontophoretic evidence that nitric oxide alters spontaneous activity of the substantia nigra pars reticulata neurons in the rat. Acta Physiol., 2006, 188, P184.
76. Sammut, S.; Bray, K.E.; West, A.R. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity. Psychopharmacology, 2007, 191, 793-803.
77. Fricchione, G.; Stefano, G.B. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries. Med. Sci. Monit., 2005, 11, MS54-MS65.
78. Nisenbaum, E.S.; Orr, W.B.; Berger, T.W. Evidence for two functionally distinct subpopulations of neurons within the rat striatum. J. Neurosci., 1988, 8, 4138-4150.
79. Ryan, L.J.; Young, S.J.; Segal, D.S.; Groves, P.M. Antidromically identified striatonigral projection neurons in the chronically implanted behaving rat: relations of cell firing to amphetamine- induced behaviors. Behav. Neurosci., 1989, 103, 3-14.
80. Kimura, M.; Kato, M.; Shimazaki, H. Physiological properties of projection neurons in the monkey striatum to the globus pallidus. Exp. Brain Res., 1990, 82, 672-676.
81. Wilson, C.J.; Chang, H.T.; Kitai, S.T. Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum. J. Neurosci., 1990, 10, 508-519.
82. Wilson, C.J.; Groves, P.M. Spontaneous firing patterns of identified spiny neurons in the rat neostriatum. Brain Res., 1981, 220, 67-80.
83. Kitai, S.T.; Surmeier, D.J. Cholinergic and dopaminergic modulation of potassium conductances in neostriatal neurons. Adv. Neurol., 1993, 60, 40-52.
84. Kish, L.J.; Palmer, M.R.; Gerhardt, G.A. Multiple single-unit recordings in the striatum of freely moving animals: effects of apomorphine and D-amphetamine in normal and unilateral 6- hydroxydopamine-lesioned rats. Brain Res., 1999, 833, 58-70.
85. Chen, M.T.; Morales, M.; Woodward, D.J.; Hoffer, B.J.; Janak, P.H. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions. Exp. Neurol., 2001, 171, 72-83.
86. DeLong, M.R. Putamen: activity of single units during slow and rapid arm movements. Science, 1973, 179, 1240-1242.
87. Crutcher, M.D.; DeLong, M.R. Single cell studies of the primate putamen. I. Functional organization. Exp. Brain Res., 1984, 53, 233-243.
88. Alexander, G.E.; DeLong, M.R. Microstimulation of the primate neostriatum. II. Somatotopic organization of striatal microexcitable zones and their relation to neuronal response properties. J. Neurophysiol., 1985, 53, 1417-1430.
89. Kimura, M.; Rajkowski, J.; Evarts, E. Tonically discharging putamen neurons exhibit set-dependent responses. Proc. Natl. Acad. Sci. USA, 1984, 81, 4998-5001.
90. Mallet, N.; Ballion, B.; Le Moine, C.; Gonon, F. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J. Neurosci., 2006, 26, 3875-3884.
91. Kawaguchi, Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J. Neurosci., 1993, 13, 4908-4923.
92. Kawaguchi, Y.; Aosaki, T.; Kubota, Y. Cholinergic and GABAergic interneurons in the striatum. Nihon Shinkei Seishin Yakurigaku Zasshi, 1997, 17, 87-90.
93. Gittis, A.H.; Nelson, A.B.; Thwin, M.T.; Palop, J.J.; Kreitzer, A.C. Distinct roles of GABAergic interneurons in the regulation of striatal output pathways. J. Neurosci., 2010, 30, 2223-2234.
94. Centonze, D.; Bracci, E.; Pisani, A.; Gubellini, P.; Bernardi, G.; Calabresi, P. Activation of dopamine D1-like receptors excites LTS interneurons of the striatum. Eur. J. Neurosci., 2002, 15, 2049-2052.
95. Bernard, V.; Laribi, O.; Levey, A.I.; Bloch, B. Subcellular redistribution of m2 muscarinic acetylcholine receptors in striatal interneurons in vivo after acute cholinergic stimulation. J. Neurosci., 1998, 18, 10207-10218.
96. Repaske, D.R.; Corbin, J.G.; Conti, M.; Goy, M.F. A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. Neuroscience, 1993, 56, 673-686.
97. Van Staveren, W.C.; Steinbusch, H.W.; Markerink-Van Ittersum, M.; Repaske, D.R.; Goy, M.F.; Kotera, J.; Omori, K.; Beavo, J.A.; De Vente, J. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol., 2003, 467, 566-580.
98. Lin, C.S. Phosphodiesterase type 5 regulation in the penile corpora cavernosa. J. Sex. Med., 2009, 6(Suppl 3), 203-209.
99. Kawaguchi, Y. Neostriatal cell subtypes and their functional roles. Neurosci. Res., 1997, 27, 1-8.
100. Calabresi, P.; Gubellini, P.; Centonze, D.; Sancesario, G.; Morello, M.; Giorgi, M.; Pisani, A.; Bernardi, G. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J. Neurosci., 1999, 19, 2489-2499.
101. West, A.R.; Grace, A.A. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci., 2002, 22, 294-304.
102. Ariano, M.A. Distribution of components of the guanosine 3',5'- phosphate system in rat caudate-putamen. Neuroscience, 1983, 10, 707-723.
103. Morello, M.; Reiner, A.; Sancesario, G.; Karle, E.J.; Bernardi, G. Ultrastructural study of nitric oxide synthase-containing striatal neurons and their relationship with parvalbumin-containing neurons in rats. Brain Res., 1997, 776, 30-39.
104. Sancesario, G.; Morello, M.; Reiner, A.; Giacomini, P.; Massa, R.; Schoen, S.; Bernardi, G. Nitrergic neurons make synapses on dual- input dendritic spines of neurons in the cerebral cortex and the striatum of the rat: implication for a postsynaptic action of nitric oxide. Neuroscience, 2000, 99, 627-642.
105. Mallet, N.; Le Moine, C.; Charpier, S.; Gonon, F. Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo. J. Neurosci., 2005, 25, 3857-3869.
106. Centonze, D.; Pisani, A.; Bonsi, P.; Giacomini, P.; Bernardi, G.; Calabresi, P. Stimulation of nitric oxide-cGMP pathway excites striatal cholinergic interneurons via protein kinase G activation. J. Neurosci., 2001, 21, 1393-1400.
107. Sardo, P.; Ferraro, G.; Di Giovanni, G.; Galati, S.; La Grutta, V. Influence of nitric oxide on the spontaneous activity of globus pallidus neurones in the rat. J. Neural Transm., 2002, 109, 1373-1389.
108. Albin, R.L.; Aldridge, J.W.; Young, A.B.; Gilman, S. Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Res., 1989, 491, 185-188.
109. Graybiel, A.M. Network-level neuroplasticity in cortico-basal ganglia pathways. Parkinsonism Relat. Disord., 2004, 10, 293-296.
110. Smith, G.S.; Price, J.C.; Lopresti, B.J.; Huang, Y.; Simpson, N.; Holt, D.; Mason, N.S.; Meltzer, C.C.; Sweet, R.A.; Nichols, T.; Sashin, D.; Mathis, C.A. Test-retest variability of serotonin 5- HT2A receptor binding measured with positron emission tomography and [18F] altanserin in the human brain. Synapse, 1998, 30, 380-392.
111. Wichmann, T.; DeLong, M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. NY Acad. Sci., 2003, 991, 199-213.
112. Atherton, J.F.; Bevan, M.D. Ionic mechanisms underlying autonomous action potential generation in the somata and dendrites of GABAergic substantia nigra pars reticulata neurons in vitro. J. Neurosci., 2005, 25, 8272-8281.
113. Richards, C.D.; Shiroyama, T.; Kitai, S.T. Electrophysiological and immunocytochemical characterization of GABA and dopamine neurons in the substantia nigra of the rat. Neuroscience, 1997, 80, 545-557.
114. Smith, Y.; Bolam, J.P. Convergence of synaptic inputs from the striatum and the globus pallidus onto identified nigrocollicular cells in the rat: a double anterograde labelling study. Neuroscience, 1991, 44, 45-73.
115. Iribe, Y.; Moore, K.; Pang, K.C.; Tepper, J.M. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J. Neurophysiol., 1999, 82, 925-933.
116. Nakanishi, H.; Kita, H.; Kitai, S.T. Intracellular study of rat substantia nigra pars reticulata neurons in an in vitro slice preparation: electrical membrane properties and response characteristics to subthalamic stimulation. Brain Res., 1987, 437, 45-55.
117. Robledo, P.; Feger, J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res., 1990, 518, 47-54.
118. Ibanez-Sandoval, O.; Carrillo-Reid, L.; Galarraga, E.; Tapia, D.; Mendoza, E.; Gomora, J.C.; Aceves, J.; Bargas, J. Bursting in substantia nigra pars reticulata neurons in vitro: possible relevance for Parkinson disease. J. Neurophysiol., 2007, 98, 2311-2323.
119. Beurrier, C.; Congar, P.; Bioulac, B.; Hammond, C. Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. J. Neurosci., 1999, 19, 599-609.
120. Di Giovanni, G.; Ferraro, G.; Sardo, P.; Di Maio, R.; Carletti, F.; La Grutta, V. Microiontophoretic Evidence that Nitric Oxide Alters Spontaneous Activity of the Substantia Nigra Pars Reticulata Neurons in the Rat. Acta Physiol., 2006, 188, P184.
121. Carletti, F.; Ferraro, G.; Rizzo, V.; D'Agostino, S.; Lonobile, G.; Sardo, P. Nitric oxide- and cGMP-active compounds affect the discharge of substantia nigra pars reticulata neurons: in vivo evidences in the rat. J. Neural Transm., 2009, 116, 539-549.
122. Galati, S.; Mazzone, P.; Fedele, E.; Pisani, A.; Peppe, A.; Pierantozzi, M.; Brusa, L.; Tropepi, D.; Moschella, V.; Raiteri, M.; Stanzione, P.; Bernardi, G.; Stefani, A. Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease. Eur. J. Neurosci., 2006, 23, 2923-2928.
123. Endoh, M.; Maiese, K.; Wagner, J.A. Expression of the neural form of nitric oxide synthase by CA1 hippocampal neurons and other central nervous system neurons. Neuroscience, 1994, 63, 679-689.
124. Sardo, P.; Carletti, F.; D'Agostino, S.; Rizzo, V.; Ferraro, G. Effects of nitric oxide-active drugs on the discharge of subthalamic neurons: microiontophoretic evidence in the rat. Eur. J. Neurosci., 2006, 24, 1995-2002.
125. Sardo, P.; Ferraro, G.; Carletti, F.; D'Agostino, S.; La Grutta, V. The discharge of subthalamic neurons is modulated by inhibiting the nitric oxide synthase in the rat. Neurosci. Lett., 2006, 396, 252-256.
126. Sardo, P.; Carletti, F.; D'Agostino, S.; Rizzo, V.; La Grutta, V.; Ferraro, G. Intensity of GABA-evoked responses is modified by nitric oxide-active compounds in the subthalamic nucleus of the rat: a microiontophoretic study. J. Neurosci. Res., 2009, 87, 2340-2350.
127. Shen, K.-Z.; Johnson, S.W. Ca2+ Influx through NMDA-Gated Channels Activates ATP-Sensitive K+ Currents through a Nitric Oxideâ "cGMP Pathway in Subthalamic Neurons. J. Neurosci., 2010, 30, 1882-1893.
128. Sardo, P.; Carletti, F.; Rizzo, V.; Lonobile, G.; Friscia, S.; Ferraro, G. Nitric oxide-active compounds modulate the intensity of glutamate-evoked responses in the globus pallidus of the rat. Life Sci., 2011, 88, 1113-1120.
129. Esposito, E.; Di Matteo, V.; Di Giovanni, G. Death in the substantia nigra: a motor tragedy. Expert Rev. Neurother., 2007, 7, 677-697.
130. Duncan, A.J.; Heales, S.J. Nitric oxide and neurological disorders. Mol. Aspects Med., 2005, 26, 67-96.
131. Zhang, L.; Dawson, V.L.; Dawson, T.M. Role of nitric oxide in Parkinson's disease. Pharmacol. Ther., 2006, 109, 33-41.
132. Hunot, S.; Boissiere, F.; Faucheux, B.; Brugg, B.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience, 1996, 72, 355-363.
133. Schulz, J.B.; Matthews, R.T.; Muqit, M.M.; Browne, S.E.; Beal, M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem., 1995, 64, 936-939.
134. Hantraye, P.; Brouillet, E.; Ferrante, R.; Palfi, S.; Dolan, R.; Matthews, R.T.; Beal, M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med., 1996, 2, 1017-1021.
135. Dawson, V.L.; Dawson, T.M. Nitric oxide in neurodegeneration. Prog. Brain Res., 1998, 118, 215-229.
136. de Vente, J.; Markerink-van Ittersum, M.; van Abeelen, J.; Emson, P.C.; Axer, H.; Steinbusch, H.W. NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain: effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis. Eur. J. Neurosci., 2000, 12, 507-519.
137. Sancesario, G.; Giorgi, M.; D'Angelo, V.; Modica, A.; Martorana, A.; Morello, M.; Bengtson, C.P.; Bernardi, G. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur. J. Neurosci., 2004, 20, 989-1000.
138. Di Giovanni, G.; Esposito, E.; Di Matteo, D. In Vivo Microdialysis in Parkinson's Research. J. Neural Transm. Suppl., 2009, 73, 223-243.
139. Kirik, D.; Rosenblad, C.; Bjorklund, A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6- hydroxydopamine in the rat. Exp. Neurol., 1998, 152, 259-277.
140. Betarbet, R.; Sherer, T.B.; Greenamyre, J.T. Animal models of Parkinson's disease. Bioessays, 2002, 24, 308-318.
141. Deumens, R.; Blokland, A.; Prickaerts, J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol., 2002, 175, 303-317.
142. Antunes, F.; Nunes, C.; Laranjinha, J.; Cadenas, E. Redox interactions of nitric oxide with dopamine and its derivatives. Toxicology, 2005, 208, 207-212.
143. Riobo, N.A.; Schopfer, F.J.; Boveris, A.D.; Cadenas, E.; Poderoso, J.J. The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic. Biol. Med., 2002, 32, 115-121.
144. Soto-Otero, R.; Mendez-Alvarez, E.; Hermida-Ameijeiras, A.; Munoz-Patino, A.M.; Labandeira-Garcia, J.L. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem., 2000, 74, 1605-1612.
145. Haik, K.L.; Shear, D.A.; Hargrove, C.; Patton, J.; Mazei-Robison, M.; Sandstrom, M.I.; Dunbar, G.L. 7-nitroindazole attenuates 6- hydroxydopamine induced spatial learning deficits and dopamine neuron loss in a presymptomatic animal model of Parkinson's disease Exp. Clin. Psychopharmacol. 2008, 16, 178-189.
146. Barc, S.; Page, G.; Barrier, L.; Piriou, A.; Fauconneau, B. Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors. Neurosci. Lett., 2001, 314, 82-86.
147. Boireau, A.; Dubedat, P.; Bordier, F.; Imperato, A.; Moussaoui, S. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology, 2000, 39, 1016-1020.
148. Gomes, M.Z.; Raisman-Vozari, R.; Del Bel, E.A. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res., 2008, 1203, 160-169.
149. Di Giovanni, G. Will it ever become possible to prevent dopaminergic neuronal degeneration? CNS Neurol. Disord. Drug Targets, 2008, 7, 28-44.
150. Jellinger, K. Alzheimer pathology in Parkinson's disease. Neurology, 1989, 39, 874-875.
151. Scherman, D.; Desnos, C.; Darchen, F.; Pollak, P.; Javoy-Agid, F.; Agid, Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol., 1989, 26, 551-557.
152. Zigmond, M.J.; Hastings, T.G.; Perez, R.G. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat. Disord., 2002, 8, 389-393.
153. Lang, A.E.; Lozano, A.M. Parkinson's disease. First of two parts. N. Engl. J. Med., 1998, 339, 1044-1053.
154. Kurosaki, R.; Muramatsu, Y.; Michimata, M.; Matsubara, M.; Kato, H.; Imai, Y.; Itoyama, Y.; Araki, T. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol. Res., 2002, 24, 655-662.
155. Jenner, P.; Dexter, D.T.; Sian, J.; Schapira, A.H.; Marsden, C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol., 1992, 32(Suppl), S82-S87.
156. Simonian, N.A.; Coyle, J.T. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol., 1996, 36, 83-106
157. Hornykiewicz, O. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease-a critical analysis of the neurochemical evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1989, 13, 319-328.
158. Dexter, D.T.; Carayon, A.; Javoy-Agid, F.; Agid, Y.; Wells, F.R.; Daniel, S.E.; Lees, A.J.; Jenner, P.; Marsden, C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 1991, 114(Pt 4), 1953-1975.
159. Watanabe, H.; Muramatsu, Y.; Kurosaki, R.; Michimata, M.; Matsubara, M.; Imai, Y.; Araki, T. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur. Neuropsychopharmacol., 2004, 14, 93-104.
160. Choi, H.J.; Jang, Y.J.; Kim, H.J.; Hwang, O. Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress. Mol. Pharmacol., 2000, 58, 633-640.
161. Galati, S.; Di Giovanni, G. Neuroprotection in Parkinson's disease: a realistic goal? CNS Neurosci. Ther., 2010, 16, 327-329.
162. Levy, N.; Horn, D.; Meilijson, I.; Ruppin, E. Distributed synchrony in a cell assembly of spiking neurons. Neural Netw., 2001, 14, 815-824.
163. Galati, S.; Stanzione, P.; D'Angelo, V.; Fedele, E.; Marzetti, F.; Sancesario, G.; Procopio, T.; Stefani, A. The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway. J. Physiol., 2009, 587, 4405-4423.
164. Galati, S.; D'Angelo, V.; Olivola, E.; Marzetti, F.; Di Giovanni, G.; Stanzione, P.; Stefani, A. Acute inactivation of the medial forebrain bundle imposes oscillations in the SNr: a challenge for the 6- OHDA model? Exp. Neurol., 2010, 225, 294-301.
165. Salum, C.; Raisman-Vozari, R.; Michel, P.P.; Gomes, M.Z.; Mitkovski, M.; Ferrario, J.E.; Ginestet, L.; Del Bel, E.A. Modulation of dopamine uptake by nitric oxide in cultured mesencephalic neurons. Brain Res., 2008, 1198, 27-33.
166. Sandi, C.; Venero, C.; Guaza, C. Decreased spontaneous motor activity and startle response in nitric oxide synthase inhibitor- treated rats. Eur. J. Pharmacol., 1995, 277, 89-97.
167. Dzoljic, E.; De Vries, R.; Dzoljic, M.R. New and potent inhibitors of nitric oxide synthase reduce motor activity in mice. Behav. Brain Res., 1997, 87, 209-212.
168. Dzoljic, E.; Nesic, Z.; Stojanovic, R.; Divac, N.; Todorovic, Z.; Vuckovic, S.; Kostic, V.; Prostran, M. Nitric oxide, neurodegeneration, and Parkinson's disease. Vojnosanit. Pregl., 2005, 62, 751-756.
169. Bockelmann, R.; Wolf, G.; Ransmayr, G.; Riederer, P. NADPH- diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J. Neural Transm. Park. Dis. Dement. Sect., 1994, 7, 115-121.
170. Stefani, A.; Fedele, E.; Galati, S.; Pepicelli, O.; Frasca, S.; Pierantozzi, M.; Peppe, A.; Brusa, L.; Orlacchio, A.; Hainsworth, A.H.; Gattoni, G.; Stanzione, P.; Bernardi, G.; Raiteri, M.; Mazzone, P. Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients. Ann Neurol., 2005, 57, 448-452.
171. Stefani, A.; Fedele, E.; Galati, S.; Raiteri, M.; Pepicelli, O.; Brusa, L.; Pierantozzi, M.; Peppe, A.; Pisani, A.; Gattoni, G.; Hainsworth, A.H.; Bernardi, G.; Stanzione, P.; Mazzone, P. Deep brain stimulation in Parkinson's disease patients: biochemical evidence. J. Nneural Transm., 2006, 401-408.
172. Chalimoniuk, M.; Langfort, J.; Lukacova, N.; Marsala, J. Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice. Biochem. Biophys. Res. Commun., 2004, 324, 118-126.
173. Bolam, J.P. Synapses of identified neurons in the neostriatum. Ciba Found. Symp., 1984, 107, 30-47.
174. Izzo, P.N.; Bolam, J.P. Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat. J. Comp. Neurol., 1988, 269, 219-234.
175. Pakhotin, P.; Bracci, E. Cholinergic interneurons control the excitatory input to the striatum. J. Neurosci., 2007, 27, 391-400.
176. Chalimoniuk, M.; Glowacka, J.; Zabielna, A.; Eckert, A.; Strosznajder, J.B. Nitric oxide alters arachidonic acid turnover in brain cortex synaptoneurosomes. Neurochem. Int., 2006, 48, 1-8.
177. Chalimoniuk, M.; Langfort, J. The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem. Int., 2007, 50, 821-833.
178. Pavon, N.; Martin, A.B.; Mendialdua, A.; Moratalla, R. ERK phosphorylation and FosB expression are associated with LDOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry, 2006, 59, 64-74.
179. Novaretti, N.; Padovan-Neto, F.E.; Tumas, V.; da-Silva, C.A.; Del Bel, E.A. Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats. Braz. J. Med. Biol. Res., 2010, 43, 1047-1053.
180. Cenci, M.A.; Lindgren, H.S. Advances in understanding L-DOPA-induced dyskinesia. Curr. Opin. Neurobiol., 2007, 17, 665-671.
181. Stefani, A.; Pierantozzi, M.; Koch, G.; Galati, S.; Stanzione, P. Therapy for Dyskinesias in Parkinson's Disease Patients. Future Neurol., 2010, 5, 277-299.
182. Cotzias, G.C.; Papavasiliou, P.S.; Gellene, R. L-dopa in parkinson's syndrome. N. Engl. J. Med., 1969, 281, 272.
183. Marsden, C.D. Parkinson's disease. Lancet, 1990, 335, 948-952.
184. Cenci, M.A.; Ohlin, K.E.; Rylander, D. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism Relat. Disord., 2009, 15(Suppl 3), S59-S63.
185. Buck, K.; Ferger, B. L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. Drug Discov. Today, 2010, 15, 867-875.
186. Padovan-Neto, F.E.; Echeverry, M.B.; Tumas, V.; Del-Bel, E.A. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience, 2009, 159, 927-935.
187. Picconi, B.; Bagetta, V.; Ghiglieri, V.; Paille, V.; Di Filippo, M.; Pendolino, V.; Tozzi, A.; Giampa, C.; Fusco, F.R.; Sgobio, C.; Calabresi, P. Inhibition of phosphodiesterases rescues striatal long- term depression and reduces levodopa-induced dyskinesia. Brain, 2011, 134, 375-387.
188. Del-Bel, E.; Padovan-Neto, F.E.; Raisman-Vozari, R.; Lazzarini, M. Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment. Curr. Pharm. Des., 2011, 17, 471-488.
189. Stefani, A.; Fedele, E.; Vitek, J.; Pierantozzi, M.; Galati, S.; Marzetti, F.; Peppe, A.; Bassi, M.S.; Bernardi, G.; Stanzione, P. The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus. Cell Death Dis., 2011, 2, e154.
190. Kashihara, K.; Sakai, K.; Marui, K.; Shohmori, T. L-DOPA does not facilitate nitric oxide production in the rat striatum and substantia nigra: in vivo microdialysis study. Life Sci., 1998, 63, PL59-64.
191. Smith, T.S.; Parker, W.D., Jr.; Bennett, J.P., Jr. L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport, 1994, 5, 1009-1011.
192. Itokawa, K.; Ohkuma, A.; Araki, N.; Tamura, N.; Shimazu, K. Effect of L-DOPA on nitric oxide production in striatum of freely mobile mice. Neurosci. lett., 2006, 402, 142-144.
193. Padovan-Neto, F.E.; Echeverry, M.B.D.; Chiavegatto, S.; Del Bel, E. Nitric oxide synthase inhibitor improves de novo and long-term L-DOPA-induced dyskinesia in hemiparkinsonian rats. Front. Syst. Neurosci., 2011, 5,
194. Chalimoniuk, M.; Stepien, A. Influence of the therapy with pergolide mesylate plus L-DOPA and with L-DOPA alone on serum cGMP level in PD patients. Pol. J. Pharmacol., 2004, 56, 647-650.
195. Qureshi, G.A.; Baig, S.; Bednar, I.; Sodersten, P.; Forsberg, G.; Siden, A. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport, 1995, 6, 1642-1644.
196. Giorgi, M.; D'Angelo, V.; Esposito, Z.; Nuccetelli, V.; Sorge, R.; Martorana, A.; Stefani, A.; Bernardi, G.; Sancesario, G. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur. J. Neurosci., 2008, 28, 941-950.